The diabetes drug semaglutide, also known as Ozempic, has a positive effect on patients with chronic kidney disease and obesity. The amount of protein in their urine decreased, as did the degree of inflammation of their kidneys and their blood pressure.

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 million patients with type 2 diabetes.

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing Alzheimer’s disease.